Antibiotic resistance: a rundown of a global crisis

References

• Singer AC, Shaw H, Rhodes V, Hart A. Review of antimicrobial resistance in the environment and its relevance to environmental regulators. Front Microbiol. 2016;7:1728.
   PubMed Web of Science ®Google Scholar
• Marshall BM, Levy SB. Food animals and antimicrobials: impacts on human health. Clin Microbiol Rev. 2011;24(4):718–733.
   PubMed Web of Science ®Google Scholar
• Nathan C, Cars O. Antibiotic resistance-problems, progress, and prospects. N Engl J Med. 2014;371(19):1761–1763.
   PubMed Web of Science ®Google Scholar
• Nathan C. Antibiotics at the crossroads. Nature. 2004;431(7011):899–902.
   PubMed Web of Science ®Google Scholar
• Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–433.
   PubMed Web of Science ®Google Scholar
• van Boeckel TP, Brower C, Gilbert M, et al. Global trends in antimicrobial use in food animals. Proc Natl Acad Sci U S A. 2015;112(18):5649–5654.
   PubMed Web of Science ®Google Scholar
• Roca I, Akova M, Baquero F, et al. The global threat of antimicrobial resistance: science for intervention. New Microbes New Infect. 2015;6:22–29.
   PubMedGoogle Scholar
• Rossolini GM, Arena F, Pecile P, Pollini S. Update on the antibiotic resistance crisis. Curr Opin Pharmacol. 2014;18:56–60.
   PubMed Web of Science ®Google Scholar
• Michael CA, Dominey-Howes D, Labbate M. The antimicrobial resistance crisis: causes, consequences, and management. Front Public Health. 2014;2:145.
   PubMedGoogle Scholar
• Spellberg B, Srinivasan A, Chambers HF. New societal approaches to empowering antibiotic stewardship. JAMA. 2016;315(12):1229–1230.
   PubMed Web of Science ®Google Scholar
• Hoffman SJ, Caleo GM, Daulaire N, et al. Strategies for achieving global collective action on antimicrobial resistance. Bull World Health Organ. 2015;93(12):867–876.
   PubMed Web of Science ®Google Scholar
• Payne DJ, Miller LF, Findlay D, Anderson J, Marks L. Time for a change: addressing R&D and commercialization challenges for antibacterials. Philos Trans R Soc Lond B Biol Sci. 2015;370(1670):20140086.
   PubMed Web of Science ®Google Scholar
• Luepke KH, Mohr JF. The antibiotic pipeline: reviving research and development and speeding drugs to market. Expert Rev Anti Infect Ther. 2017;15(5):425–433.
   PubMed Web of Science ®Google Scholar
• Landers T, Kavanagh KT. Is the Presidential Advisory Council on Combating Antibiotic Resistance missing opportunities? Am J Infect Control. 2016;44(11):1356–1359.
   PubMed Web of Science ®Google Scholar
• Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4):277–283.
   PubMedGoogle Scholar
• Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309–318.
   PubMed Web of Science ®Google Scholar
• Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–1098.
   PubMed Web of Science ®Google Scholar
• Guidos RJ. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011;52(Suppl 5):S397–S428.
   PubMedGoogle Scholar
• Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence. 2013;4(2):185–191.
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Gilbert DN, Spellberg B. Seven ways to preserve the miracle of antibiotics. Clin Infect Dis. 2013;56(10):1445–1450.
   PubMed Web of Science ®Google Scholar
• Economou V, Gousia P. Agriculture and food animals as a source of antimicrobial-resistant bacteria. Infect Drug Resist. 2015;8:49–61.
   PubMed Web of Science ®Google Scholar
• Maron DF, Smith TJ, Nachman KE. Restrictions on antimicrobial use in food animal production: an international regulatory and economic survey. Global Health. 2013;9:48.
   PubMed Web of Science ®Google Scholar
• Founou LL, Founou RC, Essack SY. Antibiotic resistance in the food chain: a developing country-perspective. Front Microbiol. 2016;7:1881.
   PubMed Web of Science ®Google Scholar
• Sengupta S, Chattopadhyay MK, Grossart HP. The multifaceted roles of antibiotics and antibiotic resistance in nature. Front Microbiol. 2013;4:47.
   PubMed Web of Science ®Google Scholar
• Piddock LJ. The crisis of no new antibiotics – what is the way forward? Lancet Infect Dis. 2012;12(3):249–253.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Gilbert DN. The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett. Clin Infect Dis. 2014;59(Suppl 2):S71–S75.
   PubMedGoogle Scholar
• Wright GD. Something old, something new: revisiting natural products in antibiotic drug discovery. Can J Microbiol. 2014;60(3):147–154.
   PubMed Web of Science ®Google Scholar
• Holmes AH, Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387(10014):176–187.
   PubMed Web of Science ®Google Scholar
• Forsberg KJ, Patel S, Gibson MK, et al. Bacterial phylogeny structures soil resistomes across habitats. Nature. 2014;509(7502):612–616.
   PubMed Web of Science ®Google Scholar
• Aminov RI. The role of antibiotics and antibiotic resistance in nature. Environ Microbiol. 2009;11(12):2970–2988.
   PubMed Web of Science ®Google Scholar
• Martinez JL. The role of natural environments in the evolution of resistance traits in pathogenic bacteria. Proc Biol Sci. 2009;276(1667):2521–2530.
   PubMed Web of Science ®Google Scholar
• Andersson DI, Hughes D. Microbiological effects of sublethal levels of antibiotics. Nat Rev Microbiol. 2014;12(7):465–478.
   PubMed Web of Science ®Google Scholar
• Morita Y, Tomida J, Kawamura Y. Responses of Pseudomonas aeruginosa to antimicrobials. Front Microbiol. 2014;4:422.
   PubMed Web of Science ®Google Scholar
• Khurshid M, Rasool MH, Ashfaq UA, Aslam B, Waseem M. Emergence of ISAba1 harboring carbapenem-resistant Acinetobacter baumannii isolates in Pakistan. Future Microbiol. 2017;12:1261–1269.
   PubMed Web of Science ®Google Scholar
• Read AF, Woods RJ. Antibiotic resistance management. Evol Med Public Health. 20142014;147(1).
   Google Scholar
• Lushniak BD. Antibiotic resistance: a public health crisis. Public Health Rep. 2014;129(4):314–316.
   PubMed Web of Science ®Google Scholar
• Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2).
   PubMed Web of Science ®Google Scholar
• Stokes HW, Gillings MR. Gene flow, mobile genetic elements and the recruitment of antibiotic resistance genes into Gram-negative pathogens. FEMS Microbiol Rev. 2011;35(5):790–819.
   PubMed Web of Science ®Google Scholar
• Wellington EM, Boxall AB, Cross P, et al. The role of the natural environment in the emergence of antibiotic resistance in Gram-negative bacteria. Lancet Infect Dis. 2013;13(2):155–165.
   PubMed Web of Science ®Google Scholar
• Lewis DA. The role of core groups in the emergence and dissemination of antimicrobial-resistant N. gonorrhoeae. Sex Transm Infect. 2013;89(Suppl 4):47–51.
   Web of Science ®Google Scholar
• Chamchod F, Ruan S. Modeling methicillin-resistant Staphylococcus aureus in hospitals: transmission dynamics, antibiotic usage and its history. Theor Biol Med Model. 2012;9:25.
   PubMed Web of Science ®Google Scholar
• Anderson ES, Lewis MJ. Drug resistance and its transfer in Salmonella typhimurium. Nature. 1965;206(984):579–583.
   PubMedGoogle Scholar
• Molbak K. Spread of resistant bacteria and resistance genes from animals to humans – the public health consequences. J Vet Med B Infect Dis Vet Public Health. 2004;51(8–9):364–369.
   PubMedGoogle Scholar
• Humphrey TJ, Jorgensen F, Frost JA, et al. Prevalence and subtypes of ciprofloxacin-resistant Campylobacter spp. in commercial poultry flocks before, during, and after treatment with fluoroquinolones. Antimicrob Agents Chemother. 2005;49(2):690–698.
   PubMed Web of Science ®Google Scholar
• Kristiansson E, Fick J, Janzon A, et al. Pyrosequencing of antibiotic-contaminated river sediments reveals high levels of resistance and gene transfer elements. PLoS One. 2011;6(2):e17038.
   PubMed Web of Science ®Google Scholar
• Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13(3):380–387.
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J. 2009;33(4):871–881.
   PubMed Web of Science ®Google Scholar
• Deleo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest. 2009;119(9):2464–2474.
   PubMed Web of Science ®Google Scholar
• Watkins RR, David MZ, Salata RA. Current concepts on the virulence mechanisms of methicillin-resistant Staphylococcus aureus. J Med Microbiol. 2012;61(Pt 9):1179–1193.
   PubMed Web of Science ®Google Scholar
• Beceiro A, Tomas M, Bou G. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin Microbiol Rev. 2013;26(2):185–230.
   PubMed Web of Science ®Google Scholar
• Martinez JL, Baquero F. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin Microbiol Rev. 2002;15(4):647–679.
   PubMed Web of Science ®Google Scholar
• Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014;6:25–64.
   PubMedGoogle Scholar
• Feldman MW, Laland KN. Gene-culture coevolutionary theory. Trends Ecol Evol. 1996;11(11):453–457.
   PubMed Web of Science ®Google Scholar
• Burrus V, Waldor MK. Shaping bacterial genomes with integrative and conjugative elements. Res Microbiol. 2004;155(5):376–386.
   PubMed Web of Science ®Google Scholar
• Handel A, Regoes RR, Antia R. The role of compensatory mutations in the emergence of drug resistance. PLoS Comput Biol. 2006;2(10):e137.
   PubMed Web of Science ®Google Scholar
• Patel R. Biofilms and antimicrobial resistance. Clin Orthop Relat Res. 2005;437:41–47.
   PubMed Web of Science ®Google Scholar
• Seral C, van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother. 2003;47(7):2283–2292.
   PubMed Web of Science ®Google Scholar
• Tsai YK, Fung CP, Lin JC, et al. Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence. Antimicrob Agents Chemother. 2011;55(4):1485–1493.
   PubMed Web of Science ®Google Scholar
• Moya B, Juan C, Alberti S, Perez JL, Oliver A. Benefit of having multiple ampD genes for acquiring beta-lactam resistance without losing fitness and virulence in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2008;52(10):3694–3700.
   PubMed Web of Science ®Google Scholar
• Yeung AT, Bains M, Hancock RE. The sensor kinase CbrA is a global regulator that modulates metabolism, virulence, and antibiotic resistance in Pseudomonas aeruginosa. J Bacteriol. 2011;193(4):918–931.
   PubMed Web of Science ®Google Scholar
• Lye DC, Earnest A, Ling ML, et al. The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: cohort study. Clin Microbiol Infect. 2012;18(5):502–508.
   PubMed Web of Science ®Google Scholar
• Sohail M, Rashid A, Aslam B, et al. Antimicrobial susceptibility of Acinetobacter clinical isolates and emerging antibiogram trends for nosocomial infection management. Rev Soc Bras Med Trop. 2016;49(3):300–304.
   PubMed Web of Science ®Google Scholar
• Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42–51.
   PubMed Web of Science ®Google Scholar
• Voulgari E, Poulou A, Koumaki V, Tsakris A. Carbapenemase-producing Enterobacteriaceae: now that the storm is finally here, how will timely detection help us fight back? Future Microbiol. 2013;8(1):27–39.
   PubMed Web of Science ®Google Scholar
• Johnson AP, Woodford N. Global spread of antibiotic resistance: the example of New Delhi metallo-beta-lactamase (NDM)-mediated carbapenem resistance. J Med Microbiol. 2013;62(Pt 4):499–513.
   PubMedGoogle Scholar
• Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev. 2011;35(5):736–755.
   PubMed Web of Science ®Google Scholar
• Lynch JP 3rd, Clark NM, Zhanel GG. Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum beta-lactamases and carbapenemases). Expert Opin Pharmacother. 2013;14(2):199–210.
   PubMed Web of Science ®Google Scholar
• Chuanchuen R, Karkhoff-Schweizer RR, Schweizer HP. High-level triclosan resistance in Pseudomonas aeruginosa is solely a result of efflux. Am J Infect Control. 2003;31(2):124–127.
   PubMed Web of Science ®Google Scholar
• Zhu L, Lin J, Ma J, Cronan JE, Wang H. Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase. Antimicrob Agents Chemother. 2010;54(2):689–698.
   PubMed Web of Science ®Google Scholar
• Randall CP, Mariner KR, Chopra I, O’Neill AJ. The target of daptomycin is absent from Escherichia coli and other Gram-negative pathogens. Antimicrob Agents Chemother. 2013;57(1):637–639.
   PubMed Web of Science ®Google Scholar
• Blake KL, O’Neill AJ. Transposon library screening for identification of genetic loci participating in intrinsic susceptibility and acquired resistance to antistaphylococcal agents. J Antimicrob Chemother. 2013;68(1):12–16.
   PubMed Web of Science ®Google Scholar
• Liu A, Tran L, Becket E, et al. Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: generating an antibiotic bar code. Antimicrob Agents Chemother. 2010;54(4):1393–1403.
   PubMed Web of Science ®Google Scholar
• Floyd JL, Smith KP, Kumar SH, Floyd JT, Varela MF. LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54(12):5406–5412.
   PubMed Web of Science ®Google Scholar
• Rm H, Liao ST, Huang CC, Huang YW, Yang TC. An inducible fusaric acid tripartite efflux pump contributes to the fusaric acid resistance in Stenotrophomonas maltophilia. PLoS One. 2012;7(12):e51053.
   PubMed Web of Science ®Google Scholar
• Kim C, Mwangi M, Chung M, Milheirico C, de Lencastre H, Tomasz A. The mechanism of heterogeneous beta-lactam resistance in MRSA: key role of the stringent stress response. PLoS One. 2013;8(12):e82814.
   PubMed Web of Science ®Google Scholar
• Ogawa W, Onishi M, Ni R, Tsuchiya T, Kuroda T. Functional study of the novel multidrug efflux pump KexD from Klebsiella pneumoniae. Gene. 2012;498(2):177–182.
   PubMed Web of Science ®Google Scholar
• Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–168.
   PubMed Web of Science ®Google Scholar
• Mohsin M, Raza S, Roschanski N, Guenther S, Ali A, Schierack P. Description of the first Escherichia coli clinical isolate harboring the colistin resistance gene mcr-1 from the Indian subcontinent. Antimicrob Agents Chemother. 2017;61(1).
   PubMed Web of Science ®Google Scholar
• Brooks BD, Brooks AE. Therapeutic strategies to combat antibiotic resistance. Adv Drug Deliv Rev. 2014;78:14–27.
   PubMed Web of Science ®Google Scholar
• Pena-Miller R, Laehnemann D, Jansen G, et al. When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transition. PLoS Biol. 2013;11(4):e1001540.
   PubMed Web of Science ®Google Scholar
• Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6(1):29–40.
   PubMed Web of Science ®Google Scholar
• Kalia VC, Wood TK, Kumar P. Evolution of resistance to quorum-sensing inhibitors. Microb Ecol. 2014;68(1):13–23.
   PubMed Web of Science ®Google Scholar
• Baveja JK, Li G, Nordon RE, et al. Biological performance of a novel synthetic furanone-based antimicrobial. Biomaterials. 2004;25(20):5013–5021.
   PubMed Web of Science ®Google Scholar
• Choi S, Isaacs A, Clements D, et al. De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers. Proc Natl Acad Sci U S A. 2009;106(17):6968–6973.
   PubMed Web of Science ®Google Scholar
• Scott RW, Degrado WF, Tew GN. De novo designed synthetic mimics of antimicrobial peptides. Curr Opin Biotechnol. 2008;19(6):620–627.
   PubMed Web of Science ®Google Scholar
• Weber T. In silico tools for the analysis of antibiotic biosynthetic pathways. Int J Med Microbiol. 2014;304(3–4):230–235.
   PubMed Web of Science ®Google Scholar
• Littmann J, Viens AM. The ethical significance of antimicrobial resistance. Public Health Ethics. 2015;8(3):209–224.
   PubMed Web of Science ®Google Scholar
• Kumar M, Curtis A, Hoskins C. Application of nanoparticle technologies in the combat against anti-microbial resistance. Pharmaceutics. 2018;10(1).
   Web of Science ®Google Scholar
• Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: present situation and prospects for the future. Int J Nanomedicine. 2017;12:1227–1249.
   PubMed Web of Science ®Google Scholar
• Brown KL, Hancock RE. Cationic host defense (antimicrobial) peptides. Curr Opin Immunol. 2006;18(1):24–30.
   PubMed Web of Science ®Google Scholar
• Forde E, Devocelle M. Pro-moieties of antimicrobial peptide prodrugs. Molecules. 2015;20(1):1210–1227.
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Haney EF, Vogel HJ. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol. 2011;29(9):464–472.
   PubMed Web of Science ®Google Scholar
• Dangel A, Ackermann N, Abdel-Hadi O, et al. A de novo-designed antimicrobial peptide with activity against multiresistant Staphylococcus aureus acting on RsbW kinase. FASEB J. 2013;27(11):4476–4488.
   PubMed Web of Science ®Google Scholar
• Hao G, Shi YH, Tang YL, Gw L. The intracellular mechanism of action on Escherichia coli of BF2-A/C, two analogues of the antimicrobial peptide Buforin 2. J Microbiol. 2013;51(2):200–206.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Kar RK, Jana J, et al. Indolicidin targets duplex DNA: structural and mechanistic insight through a combination of spectroscopy and microscopy. ChemMedChem. 2014;9(9):2052–2058.
   PubMed Web of Science ®Google Scholar
• Maria-Neto S, de Almeida KC, Macedo ML, Franco OL. Understanding bacterial resistance to antimicrobial peptides: from the surface to deep inside. Biochim Biophys Acta. 2015;1848(11 Pt B):3078–3088.
   PubMed Web of Science ®Google Scholar
• Parachin NS, Franco OL. New edge of antibiotic development: antimicrobial peptides and corresponding resistance. Front Microbiol. 2014;5:147.
   PubMed Web of Science ®Google Scholar
• Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. 1940. Rev Infect Dis. 1988;10(4):677–678.
   PubMedGoogle Scholar
• Gould IM. Antibiotic resistance: understanding how to control it. Int J Antimicrob Agents. 2012;40(3):193–195.
   PubMed Web of Science ®Google Scholar
• Jain R, Kralovic SM, Evans ME, et al. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med. 2011;364(15):1419–1430.
   PubMed Web of Science ®Google Scholar
• Gurieva T, Bootsma MC, Bonten MJ. Successful Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections revisited. Clin Infect Dis. 2012;54(11):1618–1620.
   PubMed Web of Science ®Google Scholar
• Wyllie DH, Walker AS, Miller R, et al. Decline of methicillin-resistant Staphylococcus aureus in Oxfordshire hospitals is strain-specific and preceded infection-control intensification. BMJ Open. 2011;1(1):e000160.
   PubMed Web of Science ®Google Scholar
• Sirijatuphat R, Sripanidkulchai K, Boonyasiri A, et al. Implementation of global antimicrobial resistance surveillance system (GLASS) in patients with bacteremia. PLoS One. 2018;13(1):e0190132.
   PubMed Web of Science ®Google Scholar
• Belay ED, Kile JC, Hall AJ, et al. Zoonotic disease programs for enhancing global health security. Emerg Infect Dis. 2017;23(13).
   PubMedGoogle Scholar
• Ghafur A, Mathai D, Muruganathan A, et al. The Chennai Declaration: a roadmap to tackle the challenge of antimicrobial resistance. Indian J Cancer. 2013;50(1):71–73.
   PubMed Web of Science ®Google Scholar
• Cantón R, Akóva M, Carmeli Y, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012;18(5):413–431.
   PubMed Web of Science ®Google Scholar
• Bigdeli M, Jacobs B, Tomson G, et al. Access to medicines from a health system perspective. Health Policy Plan. 2013;28(7):692–704.
   PubMed Web of Science ®Google Scholar
• Fischbach MA. Combination therapies for combating antimicrobial resistance. Curr Opin Microbiol. 2011;14(5):519–523.
   PubMed Web of Science ®Google Scholar
• Coates AR, Halls G, Hu Y. Novel classes of antibiotics or more of the same? Br J Pharmacol. 2011;163(1):184–194.
   PubMed Web of Science ®Google Scholar
• Infectious Diseases Society of America. The 10×’20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010;50(8):1081–1083.
   PubMed Web of Science ®Google Scholar
• Escaich S. Antivirulence as a new antibacterial approach for chemotherapy. Curr Opin Chem Biol. 2008;12(4):400–408.
   PubMed Web of Science ®Google Scholar
• Rex JH, Eisenstein BI, Alder J, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis. 2013;13(3):269–275.
   PubMed Web of Science ®Google Scholar
• Research programme: bacteriophage therapeutics – AmpliPhi BioSciences/Leicester and Glasgow Universities. Available from: https://adisinsight.springer.com/drugs/800039161. Accessed May 11, 2018.
   Google Scholar
• Raqib R, Sarker P, Bergman P, et al. Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci U S A. 2006;103(24):9178–9183.
   PubMed Web of Science ®Google Scholar
• Bergman P, Norlin AC, Hansen S, Björkhem-Bergman L. Vitamin D supplementation to patients with frequent respiratory tract infections: a post hoc analysis of a randomized and placebo-controlled trial. BMC Res Notes. 2015;8:391.
   PubMedGoogle Scholar
• Matsuoka O, Patel DM, Sasaki S, et al. Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults. Hum Vaccin Immunother. 2018;14(2):322–328.
   PubMed Web of Science ®Google Scholar
• Peng Z, Ling L, Stratton CW, et al. Advances in the diagnosis and treatment of Clostridium difficile infections. Emerg Microbes Infect. 2018;7(1):15.
   PubMed Web of Science ®Google Scholar
• NVB 302. Available from: https://adisinsight.springer.com/drugs/800030483. Accessed February 1, 2018.
   Google Scholar
• Research programme – plectasin antibacterials – Adenium Biotech. Available from: https://adisinsight.springer.com/drugs/800039698. Accessed February 2, 2018.
   Google Scholar
• Hernandez LD, Racine F, Xiao L, et al. Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling. Antimicrob Agents Chemother. 2015;59(2):1052–1060.
   PubMed Web of Science ®Google Scholar
• Morrison C. Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015;14(11):737–738.
   PubMed Web of Science ®Google Scholar
• Dubberke ER, Lee CH, Orenstein R, Khanna S, Hecht G, Gerding DN. Results from a randomized placebo-controlled clinical trial of a RBX2660 – a microbiota-based drug for the prevention of recurrent Clostridium difficile infection. Clin Infect Dis. Epub 2018 Mar 29.
   Google Scholar
• Seres Therapeutics. SER-109. Available from: http://www.serestherapeutics.com/clinical-trials/ecospor-trial. Accessed May 11, 2018.
   Google Scholar
• Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA. 2015;313(17):1719–1727.
   PubMed Web of Science ®Google Scholar
• Begier E, Seiden DJ, Patton M, et al. SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies. Vaccine. 2017;35(8):1132–1139.
   PubMed Web of Science ®Google Scholar
• Jun SY, Jung GM, Yoon SJ, et al. Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob Agents Chemother. 2014;58(4):2084–2088.
   PubMed Web of Science ®Google Scholar
• Schuch R, Lee HM, Schneider BC, et al. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia. J Infect Dis. 2014;209(9):1469–1478.
   PubMed Web of Science ®Google Scholar
• Hua L, Hilliard JJ, Shi Y, et al. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother. 2014;58(2):1108–1117.
   PubMed Web of Science ®Google Scholar
• Aridis Pharmaceuticals. AR-301 (Salvecin®). Available from: https://aridispharma.com/ar-301/. Accessed May 11, 2018.
   Google Scholar
• Varshney AK, Kuzmicheva GA, Lin J, et al. A natural human monoclonal antibody targeting staphylococcus protein A protects against Staphylococcus aureus bacteremia. PLoS One. 2018;13(1):e0190537.
   PubMed Web of Science ®Google Scholar
• Phase I/II trial of AmpliPhage-001 in patients with cystic fibrosis-associated Pseudomonas aeruginosa infections. Available from: https://adisinsight.springer.com/trials/700252954. Accessed May 11, 2018.
   Google Scholar
• Research programme: antibacterial protein-based therapeutics – Phico Therapeutics. Available from: https://adisinsight.springer.com/drugs/800027172. Accessed August 4, 2016.
   Google Scholar
• Westritschnig K, Hochreiter R, Wallner G, Firbas C, Schwameis M, Jilma B. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers. Hum Vaccin Immunother. 2014;10(1):170–183.
   PubMed Web of Science ®Google Scholar
• Labiotech. Swiss pharma clears €37M funding to develop a new class of antibiotics. Available from: https://labiotech.eu/polyphor-murepavadin-pol6014-funding/. Accessed May 11, 2018.
   Google Scholar
• Aridis Pharmaceuticals. AR-101 (Aerumab™). Available from: https://aridispharma.com/ar-101/. Accessed May 11, 2018.
   Google Scholar
• Aridis Pharmaceuticals. AR-105 (Aerucin®). Available from: https://aridispharma.com/ar-105/. Accessed May 11, 2018.
   Google Scholar
• Digiandomenico A, Keller AE, Gao C, et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014;6262(262):ra155.
   Google Scholar